Group 1 - Eton Pharmaceuticals reported a quarterly loss of $0.1 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.01, representing an earnings surprise of -900.00% [1] - The company posted revenues of $18.93 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 13.24%, and showing significant growth from $9.07 million a year ago [2] - Eton Pharmaceuticals has surpassed consensus revenue estimates four times over the last four quarters, indicating a positive trend in revenue performance [2] Group 2 - The stock has gained approximately 14.6% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $0.15 on revenues of $20.11 million, and for the current fiscal year, it is $0.41 on revenues of $76.98 million [7] Group 3 - The Zacks Industry Rank places the Medical - Biomedical and Genetics sector in the top 41% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Eton Pharmaceuticals currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future due to unfavorable estimate revisions [6]

Eton Pharmaceuticals (ETON) Q2 2025 Earnings Call August 07, 2025 04:30 PM ET Speaker0Thank you for standing by. My name is Alex, and I will be your conference operator for today. At this time, I would like to welcome everyone to the Eton Pharmaceutical q two twenty twenty five earnings call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session.If you would like to ask a question during this time, simply press star follo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter ...

Exhibit 99.1 "Our strong commercial execution helped us deliver an impressive 108% revenue growth in the quarter, driven primarily by ongoing growth from ALKINDI SPRINKLE and the relaunches of INCRELEX and GALZIN. INCRELEX continues to track well ahead of our original expectations with 100 active patients at the end of July. We previously expected to reach this mark at the end of the year, so we are proud of the team's hard work to hit this milestone well ahead of schedule. With these recent successes and t ...

My handle is the Michigan Value Investor, but everyone calls me MVI. I have a PhD in theoretical physics from UC Berkeley and worked briefly in the field before switching my interests to investing. I worked as an analyst at a billion dollar fund for several years before starting my own very small fund in 2009. During this time I have developed a group of stocks that I understand well, and I have excellent relations with management in many cases. This long standing familiarity with a select group of companie ...

Core Insights - Eton Pharmaceuticals has received FDA acceptance for its New Drug Application (NDA) for ET-600, with a target action date set for February 25, 2026 [1] - ET-600 is a patented formulation of desmopressin oral solution, protected until 2044, aimed at treating central diabetes insipidus in pediatric patients [1][3] - The company is preparing for a potential product launch in the first quarter of 2026, addressing a significant unmet need in pediatric endocrinology [2] Company Overview - Eton Pharmaceuticals focuses on developing and commercializing treatments for rare diseases, currently offering eight commercial products [4] - The company has five additional product candidates in late-stage development, including ET-600, Amglidia®, ET-700, ET-800, and ZENEO® hydrocortisone autoinjector [4] - ET-600 is expected to be the only oral liquid option available for pediatric patients requiring precise dosing, as current alternatives involve cutting tablets or using unapproved suspensions [2][3]

Financial Performance and Growth Strategy - Eton achieved 16 straight quarters of sequential revenue growth, driven by Alkindi Sprinkle and Carglumic Acid [14] - The company projects a clear path to over $100 million in near-term revenue with the additions of Increlex, Galzin, and ET-400 [23] - Eton expects to exit 2025 with an approximate $80 million revenue run rate [81] - The company anticipates a favorable product mix shift, expecting approximately 70% adjusted gross margin in 2025 and over 75% by 2028 [83] Product Portfolio and Pipeline - Eton has built one of the broadest ultra-rare disease portfolios in the industry, including 13 products and programs [10, 11] - The company acquired two high-value commercial products, Increlex and Galzin, and added three pipeline assets, Amglidia, ET-700, and ET-800 [19, 20] - A return of Increlex to 185 active US patients would produce estimated US revenue of approximately $50 million [28] - The company estimates that harmonizing the US definition of SPIGFD to match the EU would expand the US patient population by approximately 5x to around 1,000 patients [29] - Eton remains highly confident that sales of Alkindi Sprinkle and ET-400 will exceed $50 million annually [43] Upcoming Launches and Milestones - ET-400 has a PDUFA date of May 28, 2025, with a commercial launch planned within 1 week of PDUFA [43] - NDA submission for ET-600 is expected in April 2025 [63] - Potential NDA filing for ET-700 is estimated in 2027, with a clear path to over $100 million of peak sales after approval [54, 56]

Core Insights - Eton Pharmaceuticals has been added to the Russell 3000 and Russell 2000 Indexes, effective after the U.S. market closes on June 27, 2025, marking a significant milestone for the company [1][2]. Company Overview - Eton Pharmaceuticals is focused on developing and commercializing treatments for rare diseases, currently offering eight commercial products and five additional candidates in late-stage development [4]. Market Impact - The inclusion in the Russell indexes is expected to enhance Eton's visibility among investors and reflects the shareholder value generated over the past year [2][3]. Product Portfolio - Eton's commercial rare disease products include KHINDIVI, INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone, with late-stage candidates including ET-600, Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjector [4].

Core Insights - The article discusses the author's academic and professional background in Machine Learning, Economics, and Finance, highlighting affiliations with prestigious institutions and experience in financial advisory, particularly in banking and mergers & acquisitions [1]. Group 1 - The author holds a PhD in Machine Learning with a focus on Economics and Finance [1]. - The author has academic affiliations with IESE Business School, ESADE Business School, and the Barcelona Supercomputing Center [1]. - The professional experience includes working at Deloitte Financial Advisory, specializing in banking and mergers & acquisitions [1]. Group 2 - The author's interests include machine learning and generative AI applications in finance and economics [1]. - The author is proficient in programming languages such as Python, R, and SQL [1].

Core Viewpoint - Eton Pharmaceuticals, Inc. (ETON) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates which is expected to positively influence its stock price [1][4]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for Eton Pharmaceuticals indicates an expected earnings per share (EPS) of $0.56 for the fiscal year ending December 2025, reflecting a significant year-over-year increase of 473.3% [9]. - Over the past three months, the Zacks Consensus Estimate for Eton has risen by 13.1%, showcasing a trend of increasing earnings estimates [9]. Zacks Rating System - The Zacks rating system is based on changes in a company's earnings picture, which is a critical factor in stock price movements [2][5]. - The system classifies stocks into five groups, with Zacks Rank 1 (Strong Buy) to Zacks Rank 5 (Strong Sell), and has a proven track record of generating an average annual return of +25% for Zacks Rank 1 stocks since 1988 [8][10]. - Eton Pharmaceuticals' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [11].